Cargando…

New treatment options to reduce heart failure hospitalization

Detalles Bibliográficos
Autores principales:	Papp, Zoltán, Tóth, Attila
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754716/ https://www.ncbi.nlm.nih.gov/pubmed/33271634 http://dx.doi.org/10.1002/ehf2.13171

Ejemplares similares

ESC Heart Failure increases its impact factor
por: Anker, Markus S., et al.
Publicado: (2020)

Creating an impact, not an impression: ESC Heart Failure in its seventh year
por: von Haehling, Stephan, et al.
Publicado: (2021)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) IV: Circulating ACE2 as a Biomarker of Systolic Dysfunction in Human Hypertension and Heart Failure
por: Úri, Katalin, et al.
Publicado: (2014)

Beta-Blockers in Heart Failure with Preserved Ejection Fraction: Could Their Use Be Vindicated as an Acceptable Option in the Future Treatment Guideline?
por: Cho, Jae Yeong
Publicado: (2019)

Commentary: Stimulating new options for heart failure management
por: Ryan, Christopher T., et al.
Publicado: (2022)

Recognizing early signs in the translational phase is essential for drug development in cardiovascular medicine
por: Papp, Zoltán, et al.
Publicado: (2023)

Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure?
por: Mann, Douglas L., et al.
Publicado: (2017)

Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction: The Misleading Definition of the New Guidelines
por: Fedele, Francesco, et al.
Publicado: (2017)

Novel Strategies Reflect the Paradigm Shift in the Treatment of Heart Failure with Reduced Ejection Fraction
por: Kida, Keisuke
Publicado: (2021)

Alternatives to Transplantation in the Treatment of Heart Failure: New Diagnostic and Therapeutic Insights
por: Nicolini, Francesco, et al.
Publicado: (2015)

Sympathetic activation in heart failure with reduced and mildly reduced ejection fraction: the role of aetiology
por: Urbancsek, Réka, et al.
Publicado: (2021)

The treatment of heart failure: an ideal challenge for the heart team
por: Reichenspurner, Hermann
Publicado: (2019)

Cell-to-cell variability in troponin I phosphorylation in a porcine model of pacing-induced heart failure
por: Czuriga, Dániel, et al.
Publicado: (2012)

Reviving the origins: acoustic biomarkers of heart failure with preserved ejection fraction
por: Tokodi, Márton, et al.
Publicado: (2022)

Tolvaptan in the very elderly with acute decompensated heart failure-a therapeutic option worth of consideration
por: Ndrepepa, Gjin
Publicado: (2017)

Surgical treatment concepts for heart failure
por: Delmo Walter, E M, et al.
Publicado: (2013)

Tapentadol: a new option for the treatment of cancer and noncancer pains
por: Dickenson, Anthony H, et al.
Publicado: (2019)

Advanced endometrial cancer: New medical treatment options on the horizon
por: Vistad, Ingvild, et al.
Publicado: (2023)

Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy
por: Lódi, Mária, et al.
Publicado: (2019)

The prevalence and clinical significance of anemia in patients hospitalized with acute heart failure
por: Frigy, Attila, et al.
Publicado: (2017)

Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction
por: Girerd, Nicolas, et al.
Publicado: (2022)

International Journal of Heart Failure: a New Journal for the Advancement of Knowledge, Experience and Science in the Field of Heart Failure
por: Park, Seong-Mi
Publicado: (2019)

Toward a New Heart Failure Registry in Korea
por: Youn, Jong-Chan, et al.
Publicado: (2017)

Cardiac Myosin Activation in the Treatment of Congestive Heart Failure: New Therapeutic Options and Review of Literature
por: Ali, Arroj, et al.
Publicado: (2021)

Present and Prospective Diagnostic and Therapeutic Options for Repeated IVF Failures
por: Sadeghi, Mohammad Reza
Publicado: (2012)

After having changed the treatment of heart failure with reduced ejection fraction: what are the latest evidences with sacubitril valsartan?
por: Kaplinsky, Edgardo
Publicado: (2019)

Inotropes and Inodilators for Acute Heart Failure: Sarcomere Active Drugs in Focus
por: Nagy, László, et al.
Publicado: (2014)

A new paradigm for the treatment of volume overload in heart failure-combined effect of tolvaptan with furosemide
por: Okamoto, Hiroshi
Publicado: (2013)

ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction
por: Kang, Min-Kyung
Publicado: (2020)

A Small Animal Model of Diabetic Heart Failure With Reduced Ejection Fraction
por: Jung, Seung-Hyun, et al.
Publicado: (2023)

Heart Failure
por: Giamouzis, Gregory, et al.
Publicado: (2011)

Heart Failure
por: Wang, Yanggan, et al.
Publicado: (2014)

Heart Diseases of Uncertain Etiology: A New Definition of Heart Failure for Epidemiological Studies
por: Puddu, Paolo Emilio, et al.
Publicado: (2023)

The London PCHF: A new Postgraduate Course on Heart Failure
por: Lüscher, Thomas F.
Publicado: (2019)

Cardiac stem cells: A promising treatment option for heart failure
por: ZHAO, XIAOHUI, et al.
Publicado: (2013)

Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma
por: Proskuriakova, Ekaterina, et al.
Publicado: (2021)

Heart Failure With Preserved Ejection Fraction in Women: New Clues to Causes and Treatment
por: Barton, Matthias, et al.
Publicado: (2020)

Percutaneous Treatment of Functional Mitral Regurgitation in Heart Failure
por: Attizzani, Guilherme F., et al.
Publicado: (2014)

Heart Failure: An Exploration of Recent Advances in Research and Treatment
por: Shoucri, Rachad, et al.
Publicado: (2016)

Eltrombopag: a new treatment option for chronic refractory adult immune thrombocytopenia
por: Park, Rojin
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gu3ur7tv5qstqvlq2lmg91d7fs